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OBJECTIVES: Previous studies have documented the impact of bacteremia involv-
ing Methicillin-resistance (MRSA) in patients with Staphylococcus aureus bactere-
mia, but recent estimates using nationally representative data are not available.
This study compares in-hospital mortality, length of stay (LOS) and total costs
between hospital discharges for MRSA and methicillin-susceptible (MSSA) S. au-
reus bacteremia. METHODS: Using the 2008-2009 Nationwide Inpatient Sample
(NIS) data of the Healthcare Cost and Utilization Project, we developed two groups
(age18 years): MRSA bacteremia (ICD-9-CM codes: 041.12, V09.0 and 790.7) and
MSSA bacteremia (ICD-9-CM codes: 041.11 and 790.7). Given the skewed distribu-
tion of in-hospital costs and over-dispersion of LOS, generalized linear model (GLM)
with gamma and negative binomial variance functions were evaluated to compare
in-hospital costs and LOS, respectively, between groups. Logit model was used to
compare inpatient mortality between groups. Gender, age, payer, 11 comorbidities,
and hospital characteristics, including hospital location, teaching status, bed size,
ownership type, and hospital region served as covariates in all regression models.
RESULTS: Patients with MRSA (vs. MSSA) bacteremia were reported as a discharge
diagnosis for 0.06% (vs. 0.05%) or 44,157 (vs. 37,653) of all hospital inpatient stays
among adults. MRSA bacteremia inpatients had relatively longer length of hospital
stay (12.5 vs. 11.1 days;P0.01), higher total costs ($22,263 vs. $21,330;P0.02), and
increased risk of in-hospital death (2.97% vs. 2.71%;P0.29) than inpatients with
MSSA bacteremia. After adjustment for patient and hospital characteristics, MRSA
bacteremia incurred 10.5% (CI:7.2-14.0%;P0.01) longer stays, 5.6% (CI:2.0-9.4%;
P0.01) higher inpatient costs, and 0.3% (CI:17.5-22.0%;P0.97) higher inpatient
mortality than MSSA bacteremia. The annual adjusted mean incremental total
inpatient cost associated with MRSA was $1,159 (SE: $379;P0.01) per
patient-discharge. CONCLUSIONS:MRSA bacteremia represents a considerable at-
tributable burden relative to MSSA bacteremia in the US hospitals. Continued ef-
forts towards preventing MRSA infections would provide significant potential ben-
efits by reducing hospital resource use and costs.
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CLINICAL AND ECONOMIC BURDEN OF COMMUNITY ACQUIRED PNEUMONIA
IN 7 COUNTRIES. A COMPARISON WITH INVASIVE PNEUMOCOCCAL DISEASE
Delgleize E, Topachevskyi O
GlaxoSmithKline Vaccines, Wavre, Belgium
OBJECTIVES:To compare the clinical and economic burden of community acquired
pneumonia (CAP) with invasive pneumococcal diseases (IPD) in children less than
10 years of age, based on cost-effectiveness studies from 7 countries. METHODS:
The clinical and economic burden of IPD and CAP hospitalisations in children less
than 10 years of age over 1 year was modelled based on published cost-effective-
ness studies of pneumococcal vaccines in UK, Canada, Czech Republic, Sweden,
Turkey, Saudi Arabia and Taiwan. Only direct medical costs were taken into ac-
count. The costs were converted in 2005 PPP adjusted international dollars (I$).
RESULTS: Model projections indicate that hospitalised CAP is more prevalent than
hospitalised IPD in children. The IPD case fatality ratio was found to be higher than
for CAP in all 7 countries evaluated. The projected total number of deaths related to
CAP was, however, estimated to be higher than for those of IPD in all countries
except in Canada and Sweden. The total estimated direct medical costs of CAP
compared with IPD were found to be on average 8.2 times higher in Europe and
North America and 37.8 times higher in Middle East and Asia Pacific regions. The
total CAP economic burden per year in children in the included studies was esti-
mated at: 57Mio I$ in UK; 65Mio I$ in Canada; 8.6Mio I$ in Czech Republic; 10.7Mio
I$ in Sweden; 3Mio I$ in Turkey; 5.7Mio I$ in Saudi Arabia and 30.3Mio I$ in Taiwan.
CONCLUSIONS: Model projections indicate that the mortality burden of CAP was
found to be higher than for IPD in the majority of countries studied. The total
economic burden of CAP in children is on average 8.2-37.8 times higher than for IPD
across 7 countries.
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OBJECTIVES: To collect real world data on length of stay and attributable costs at
hospital wards for patients with CDI in a Swedish inpatient care setting.METHODS:
The CEBRxA database was used, which combines data from a health resource
utilization database for inhabitants in the greater Gothenburg area, with national
Swedish registers on prescription drug use and mortality. All CDI events (ICD-10
code A04.7) were collected during the years 2005 to 2009. CDI admissions were
defined as new or recurrent, i.e. new admission within 42 days from discharge. CDI
care contacts were explored in the strata of new-/recurrent CDI with CDI diagnose
in primary/other position. RESULTS: A total of 2,338 care contacts (1,689 patients)
of which 82% was inpatient, were identified. New CDI care contacts accounted for
1,883 and recurrent care contacts for 455. Recurrent care contacts were 1.36 times
more likely to have the CDI diagnosis in first position compared to new care con-
tacts (P3.078e-10), corresponding to 64% (290/455). The mean length of stay for
recurrent care contacts, with CDI in other diagnose positions, was 15.9 days com-
pared to CDI in primary position, 7.3 days. The mean cost for recurrent CDI in
primary position was 24,710SEK and 57,910SEK for CDI in other diagnose position.
When allowing the CDI diagnosis to be in any position, the mean length of stay was
10.5 days with a mean cost of 37,020SEK.CONCLUSIONS:The mean cost and length
of stay for patients with CDI varied considerably depending on whether the CDI
diagnosis was in primary position or included as a complicating factor to pre-
existing disease, i.e. other diagnose position. There would be a large potential for
cost savings if recurrent CDI could be avoided.
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COST IMPLICATIONS OF DIFFERENT PRACTICES IN VACCINE PROVISION
Maervoet J, Pasmans R, Saka Ö
Deloitte, Diegem, Belgium
OBJECTIVES: Given that vaccination systems vary widely between countries, we
investigated the cost implications of different ways of organising vaccine provision
in order to identify best practices.METHODS:We evaluated vaccination systems in
six EU countries by investigating the provision of several paediatric and adult vac-
cines. We validated our findings through interviews with academics, country ex-
perts and executives from large vaccine manufactures. We built a tool to simulate
the impact of alternative policies on all cost components relevant in vaccine
provision. RESULTS: Our findings suggest that vaccine procurement, distribution
and administration are the three key areas for potential efficiency gains for vaccine
provision. While procurement through tenders requires careful planning and prep-
aration, it does seem to be an effective, short-term method for health care payers to
obtain lower vaccine purchase prices. Policy makers may, however, need to con-
sider that anticipated savings can be partly offset by increased wastage due to
over-ordering and losses in social contributions. Examples from the six investi-
gated countries confirm these cost components can become relevant. The main
economical benefits may lie further downstream: i.e. in a more efficient provision
of vaccines through alternative distribution and vaccine administration channels.
Distribution can be organised directly to pharmacies or vaccinators by specialised
cold chain logistics providers (such as for childhood vaccine distribution in UK)
while the number and types of vaccinations settings can be extended to non-
traditional settings such as schools (Belgium), pharmacies (Ireland), and vaccina-
tion centres (Greece). Based on “what-if simulations”, common efficiency gains of
€10 to €15 per vaccination might be achieved in distribution and administration.
CONCLUSIONS: By applying best practices in the distinct areas of vaccine procure-
ment, distribution and administration, vaccine provision can be organised in a
more cost-effective way. Policy makers should take these into consideration when
choosing a specific practice for vaccine provision.
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EUROPEAN REFERENCE PRICING FOR VACCINES IN GERMANY: MECHANICS
AND EFFECTS
Hammerschmidt T1, Barth J2
1GlaxoSmithKline, Munich, Germany, 2-, Feucht, Germany
OBJECTIVES: In 2011, Germany introduced a European reference pricing (ERP) sys-
tem for vaccines in order to bring down the German vaccine prices to an assumed
smaller European level. Description of the mechanism of the ERP-system. Analysis
of effects on prices in the vaccine portfolio of GlaxoSmithKline (GSK). Further, we
evaluate the impact of ERP-system in the influenza vaccine market (8 vaccines, 5
manufacturers). METHODS: The description of the mechanism is based on the law
and corresponding regulations of the head association of sickness funds (GKV-SV).
We analyze the relation of the German and the European reference prices in the
GSK portfolio. In the influenza market, we analyze the price reduction and the
spread of prices before and after reference pricing. RESULTS: According to German
law, ERP is based on manufacturer-selling-prices in four European countries with a
gross domestic product (GDP) matching Germany best (i.e. UK, France, Italy, Spain)
weighted by purchasing-power-parities (PPP) and sales. GKV-SV extended this bas-
ket to the countries with closest GDP to Germany in which the vaccine is marketed.
Only 9 of 20 GSK-vaccines are marketed in the four countries considered by the law,
Poland and Belgium become relevant countries in the extended basket. For 10
vaccines, GlaxoSmithKline pays a mean rebate of 38% (min:2%,max:66%;95%-CI:
[25%;51%]). For the remaining 10 vaccines the ERP is 18%(min:1%,max:79%;95%-CI:
[3%;33%]) above the German price. In the flu vaccine market, ERP-system reduces
the pharmacy-selling-prices by 37%-69% (pack size 1) or 32%-63% (pack size 10) and
widens the price range from 10% to 118% (pack size 1) or 6% to 84% (pack size 10)
while changing the price order of the vaccines.CONCLUSIONS: European reference
prices are not generally lower than German prices. In the most competitive vaccine
market of influenza vaccines, the ERP-system lowers the prices, but seems to dis-
tort the market prices.
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TOWARDS BEST PRACTICES FOR HANDLING UNCERTAINTIES IN HEALTH
TECHNOLOGY ASSESSMENTS FOR HPV VACCINATION TO BETTER INFORM
DECISION MAKING
Siebert U1, Castellsague X2, Lee Mortensen G3, La Torre G4
1UMIT/ Oncotyrol/ Harvard University, Hall i.T.;Innsbruck, Tyrol, Austria, 2Institut Català
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OBJECTIVES: HTAs for human papillomavirus (HPV) vaccination have been con-
ducted by health authorities or HTA agencies in most western European countries
and played an important role in the decision-making for implementing HPV vac-
cination in girls. Our research aims to stress lessons learnt from past HTAs and to
suggest general best practices for future HTAs of HPV vaccination. METHODS: A
comprehensive research was conducted into the current HTA landscape in West-
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